News & Updates
Filter by Specialty:
Guselkumab yields durable benefit in biologic-naïve PsA patients
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.
Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021
Finerenone lessens HF burden among patients with CKD, diabetes
Treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone helps prevent the incidence of new-onset heart failure (HF) and improve other HF outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as shown in a secondary analysis of the phase III FIGARO-DKD trial.
Finerenone lessens HF burden among patients with CKD, diabetes
22 Nov 2021
Beta-blocker withdrawal improves functional capacity in HFpEF
Withdrawal of beta-blocker treatment has led to increased maximal functional capacity in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence, reports a recent study, noting how use of beta-blockers deserved re-evaluation.
Beta-blocker withdrawal improves functional capacity in HFpEF
20 Nov 2021
AKI post-AMI tied to more serious kidney outcomes
Patients who develop acute kidney injury (AKI) following an acute myocardial infarction (AMI) have an elevated risk of more serious kidney outcomes including persistent reductions in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), or renal death, according to results of the PARADISE-MI trial.